The development of a CDK2-docking site peptide that inhibits p53 and sensitizes cells to death.
Ferguson M, Luciani MG, Finlan L, Rankin EM, Ibbotson S, Fersht A, Hupp TR, Cell Cycle, 2004 Jan - link